Clinic
Park Duvalle Community Health Center, INC.
Park Duvalle Community Health Center, INC. was paid $8.23M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
33Billing provider infoPARK DUVALLE COMMUNITY HEALTH CENTER, INC.
LOUISVILLE, KY 40211
LOUISVILLE, KY 40211
33aNPI1245253160assigned 07/25/2006
33bProvider typeFederally Qualified Health Center (FQHC)
28Total paid$8.23M
24GClaims731,784
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Federally Qualified Health Center (FQHC) providers in Kentucky
Rank by total paid#9 of 37
Median peer was paid$1.29M
This provider vs. median6.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,586 | $1.48M | |
| 2019 | 64,453 | $985K | |
| 2020 | 78,435 | $1.34M | |
| 2021 | 121,129 | $1.33M | |
| 2022 | 110,762 | $1.22M | |
| 2023 | 166,586 | $1.09M | |
| 2024incomplete | 99,833 | $787K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 67,997 | 59,421 | $2.23M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 27,439 | 24,330 | $1.35M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.8% | 14,733 | 13,133 | $316K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.2% | 9,566 | 8,668 | $261K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.4% | 5,655 | 4,226 | $198K |
| 80050 | General health panel | 2.3% | 5,391 | 4,829 | $188K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.1% | 6,207 | 5,558 | $177K |
| 80061 | Lipid panel | 2.1% | 17,950 | 16,275 | $176K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 2.0% | 2,450 | 2,112 | $166K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.9% | 3,010 | 2,825 | $158K |
| D0330 | Panoramic radiographic image | 1.8% | 4,201 | 3,808 | $146K |
| 99408 | 1.6% | 9,016 | 8,340 | $134K |
196 more codes
| D0140 | Limited oral evaluation - problem focused | 1.5% | 4,179 | $127K |
| D0150 | Comprehensive oral evaluation - new or established patient | 1.5% | 4,461 | $125K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 889 | $95K |
| 99442 | 1.1% | 2,466 | $94K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 10,413 | $93K |
| 99173 | 1.1% | 3,701 | $89K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.1% | 3,566 | $88K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 14,326 | $88K |
| 80053 | Comprehensive metabolic panel | 1.0% | 11,857 | $85K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.0% | 2,576 | $83K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.0% | 1,481 | $83K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,429 | $82K |
| G0467 | Community health center visit, returning patient | <1% | 10,892 | $81K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 8,806 | $65K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,416 | $62K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,015 | $62K |
| 99490 | Ccm add 20min | <1% | 2,094 | $62K |
| D0274 | Bitewings - four radiographic images | <1% | 3,060 | $61K |
| 99441 | <1% | 2,395 | $60K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,196 | $59K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 737 | $57K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,840 | $55K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,846 | $53K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,607 | $44K |
| 82652 | <1% | 1,676 | $43K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 714 | $39K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,896 | $38K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 469 | $34K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 906 | $32K |
| 99439 | <1% | 1,232 | $30K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,043 | $30K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 788 | $29K |
| 87806 | <1% | 1,049 | $28K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 421 | $25K |
| D9110 | <1% | 795 | $25K | |
| D1110 | Prophylaxis - adult | <1% | 733 | $25K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 341 | $23K |
| 99443 | <1% | 537 | $22K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 289 | $22K |
| 82607 | <1% | 2,164 | $22K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 4,955 | $21K |
| G0511 | Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month | <1% | 2,054 | $17K |
| 84703 | <1% | 2,793 | $17K | |
| 81001 | <1% | 8,505 | $17K | |
| 90670 | <1% | 1,048 | $17K | |
| 99386 | <1% | 281 | $16K | |
| 87210 | <1% | 3,928 | $15K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,201 | $14K |
| 82947 | <1% | 6,000 | $13K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 358 | $12K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,305 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,085 | $12K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 221 | $11K |
| 86703 | <1% | 885 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,416 | $9K |
| 81003 | <1% | 7,705 | $8K | |
| 90461 | <1% | 2,608 | $8K | |
| 99174 | <1% | 549 | $8K | |
| 92551 | <1% | 804 | $7K | |
| 84153 | <1% | 584 | $7K | |
| 82570 | <1% | 1,848 | $7K | |
| 81025 | <1% | 1,041 | $7K | |
| 86592 | <1% | 1,753 | $6K | |
| 99406 | <1% | 1,156 | $6K | |
| 96127 | <1% | 2,336 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 95 | $5K |
| 84439 | <1% | 857 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 338 | $5K |
| 99177 | <1% | 1,965 | $4K | |
| 90633 | <1% | 803 | $4K | |
| 99385 | <1% | 57 | $4K | |
| 97802 | <1% | 1,057 | $4K | |
| 99383 | <1% | 58 | $4K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 200 | $4K |
| 0012A | <1% | 132 | $4K | |
| 82043 | <1% | 865 | $4K | |
| 0001A | <1% | 187 | $4K | |
| 90649 | <1% | 203 | $4K | |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | <1% | 207 | $3K |
| D4341 | <1% | 73 | $3K | |
| 90647 | <1% | 431 | $3K | |
| 82948 | <1% | 757 | $3K | |
| 92552 | <1% | 358 | $3K | |
| 0002A | <1% | 94 | $3K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 608 | $3K |
| 0011A | <1% | 127 | $3K | |
| 87340 | <1% | 400 | $3K | |
| 90680 | <1% | 373 | $3K | |
| 90658 | <1% | 446 | $3K | |
| 82962 | <1% | 1,115 | $3K | |
| 85027 | <1% | 449 | $2K | |
| 81002 | <1% | 2,304 | $2K | |
| 90688 | <1% | 174 | $2K | |
| 96160 | <1% | 2,369 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 90 | $2K |
| 99188 | <1% | 149 | $2K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 41 | $2K |
| 80074 | <1% | 85 | $2K | |
| 82274 | <1% | 132 | $2K | |
| 99195 | <1% | 189 | $2K | |
| 90845 | <1% | 53 | $2K | |
| 90674 | <1% | 82 | $1K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 35 | $1K |
| 90716 | <1% | 124 | $1K | |
| 91320 | <1% | 16 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $981.35 |
| 90707 | <1% | 80 | $968.31 | |
| 84436 | <1% | 220 | $964.60 | |
| 90723 | <1% | 156 | $946.40 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 224 | $884.15 |
| 90686 | <1% | 362 | $883.89 | |
| 90734 | <1% | 342 | $873.67 | |
| 86803 | <1% | 76 | $853.98 | |
| 87070 | <1% | 85 | $674.80 | |
| 90715 | <1% | 195 | $645.96 | |
| 36416 | <1% | 253 | $619.52 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $551.58 |
| 0064A | <1% | 14 | $520.00 | |
| 86580 | <1% | 94 | $511.18 | |
| 87430 | <1% | 35 | $508.52 | |
| 99447 | <1% | 13 | $479.97 | |
| G0071 | Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | <1% | 57 | $479.27 |
| 99381 | <1% | 16 | $471.48 | |
| 99384 | <1% | 14 | $437.96 | |
| 0031A | <1% | 15 | $385.00 | |
| 90657 | <1% | 60 | $377.86 | |
| 87081 | <1% | 63 | $349.71 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 13 | $313.82 |
| 90656 | <1% | 17 | $311.56 | |
| 90480 | <1% | 16 | $310.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $283.90 |
| 99446 | <1% | 28 | $281.17 | |
| 93000 | <1% | 14 | $266.91 | |
| 90651 | <1% | 285 | $253.79 | |
| 87088 | <1% | 48 | $250.88 | |
| 84481 | <1% | 15 | $224.47 | |
| 98967 | <1% | 14 | $198.30 | |
| 86403 | <1% | 26 | $197.72 | |
| 90473 | <1% | 59 | $189.79 | |
| 82746 | <1% | 18 | $149.94 | |
| 98960 | <1% | 16,596 | $122.61 | |
| 96156 | <1% | 41 | $117.92 | |
| 97803 | <1% | 90 | $110.18 | |
| 3074F | <1% | 28,270 | $106.80 | |
| 98966 | <1% | 14 | $103.40 | |
| 84480 | <1% | 16 | $94.40 | |
| 1160F | <1% | 57,783 | $77.51 | |
| 81528 | Oncology (colorectal) screening, quantitative real-time target and signal amplification | <1% | 31 | $75.00 |
| 99000 | <1% | 11,117 | $71.21 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 11,959 | $67.14 |
| D0180 | <1% | 308 | $66.30 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 29 | $54.05 |
| 82950 | <1% | 17 | $52.41 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 16 | $51.33 |
| 1126F | <1% | 53,636 | $48.65 | |
| 90744 | <1% | 24 | $48.44 | |
| 3008F | <1% | 37,336 | $45.09 | |
| 3078F | <1% | 23,322 | $42.86 | |
| 1159F | <1% | 19,921 | $36.92 | |
| 3079F | <1% | 14,812 | $30.63 | |
| 3077F | <1% | 9,410 | $19.45 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 6,864 | $17.97 |
| 1125F | <1% | 19,368 | $15.60 | |
| 3080F | <1% | 5,666 | $12.82 | |
| 3075F | <1% | 5,704 | $12.27 | |
| 1036F | <1% | 5,753 | $6.97 | |
| 3044F | <1% | 1,643 | $4.93 | |
| 0521F | <1% | 5,831 | $2.81 | |
| 3048F | <1% | 1,536 | $1.98 | |
| 2014F | <1% | 1,716 | $0.94 | |
| 99407 | <1% | 116 | $0.71 | |
| 91300 | <1% | 460 | $0.27 | |
| 3049F | <1% | 291 | $0.13 | |
| 3085F | <1% | 395 | $0.11 | |
| 91301 | <1% | 411 | $0.05 | |
| 91307 | <1% | 20 | $0.02 | |
| 3061F | <1% | 33 | $0.02 | |
| 90671 | <1% | 88 | $0.01 | |
| 91306 | <1% | 23 | $0.01 | |
| 4004F | 0% | 340 | $0.00 | |
| 2028F | 0% | 58 | $0.00 | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | 0% | 30 | $0.00 |
| 90687 | 0% | 20 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 103 | $0.00 |
| 90713 | 0% | 25 | $0.00 | |
| 90710 | 0% | 22 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 2,351 | $0.00 |
| 1034F | 0% | 1,236 | $0.00 | |
| 3120F | 0% | 49 | $0.00 | |
| 90620 | 0% | 43 | $0.00 | |
| 90677 | 0% | 129 | $0.00 | |
| 90697 | 0% | 38 | $0.00 | |
| D9995 | 0% | 164 | $0.00 | |
| 90660 | 0% | 17 | $0.00 | |
| 90696 | 0% | 20 | $0.00 | |
| 99090 | 0% | 73 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJETT, SWANNIE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Park Duvalle Community Health Center, INC. | Taylorsville, KY | $63K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.